EAM Investors’s Travere Therapeutics TVTX Stock Holding History

EAM Investors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.7M	Buy	+117,987	New	+$5.23M	0.6%	43
2026 Q1	–	Sell	-109,404	Closed	-$4.18M	–	377
2025 Q4	$4.18M	Buy	+109,404	New	+$3.56M	0.47%	113
2025 Q2	–	Sell	-150,286	Closed	-$2.69M	–	351
2025 Q1	$2.69M	Buy	+150,286	New	+$3.05M	0.47%	108
2016 Q4	–	Sell	-31,611	Closed	-$707K	–	367
2016 Q3	$707K	Buy	+31,611	New	+$602K	0.1%	285
2015 Q3	–	Sell	-43,616	Closed	-$1.45M	–	341
2015 Q2	$1.45M	Buy	+43,616	New	+$1.19M	0.17%	234

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM Investors's TVTX Position: Q2 2026 in Review

EAM Investors opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 117,987 shares worth $6.7M. The stake represents 0.6% of the portfolio and ranks #43 among its holdings. This is a return to the name: EAM Investors previously reported a position in TVTX as recently as Q4 2025.

EAM Investors first reported a position in TVTX in Q2 2015 and has held it in 5 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

EAM Investors held 117,987 shares of Travere Therapeutics worth $6.7M as of Q2 2026.
Travere Therapeutics was a new EAM Investors position in Q2 2026.
Travere Therapeutics made up 0.6% of EAM Investors's portfolio in Q2 2026, its #43 holding.
EAM Investors first reported a position in Travere Therapeutics in Q2 2015 and has held it in 5 quarters since.
321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.